Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 1/20 | 0.54 |
| ▸ | ARG1 | P05089 | 5/20 | 0.53 |
| ▸ | ARG2 | P78540 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5704293 | 1.00 | SLC1A2 (0.54) | SLC1A2ARG1ARG2MEN1BLM | |
| SCHEMBL14216687 | 1.00 | SLC1A2 (0.54) | SLC1A2ARG1ARG2MEN1BLM | |
| SCHEMBL2033261 | 1.00 | SLC1A2 (0.54) | SLC1A2ARG1ARG2MEN1BLM | |
| SCHEMBL7672628 | 1.00 | SLC1A2 (0.54) | SLC1A2ARG1ARG2MEN1BLM | |
| SCHEMBL2033263 | 1.00 | SLC1A2 (0.54) | SLC1A2ARG1ARG2MEN1BLM | |
| Hydrochloric Acid SCHEMBL7748845 | 0.98 | SLC1A2 (0.52) | SLC1A2ARG1ARG2MEN1BLM | |
| Hydrochloric Acid SCHEMBL7748836 | 0.98 | SLC1A2 (0.52) | SLC1A2ARG1ARG2MEN1BLM | |
| Hydrochloric Acid SCHEMBL7748843 | 0.98 | SLC1A2 (0.52) | SLC1A2ARG1ARG2MEN1BLM | |
| SCHEMBL16056702 | 0.88 | ARG1 (0.59) | SLC1A2ARG1ARG2MEN1BLM | |
| Hydrochloric Acid SCHEMBL7809370 | 0.86 | ARG1 (0.43) | SLC1A2ARG1ARG2MEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011085393-A1 | STABLE INSULIN FORMULATIONS AND METHODS OF MAKING AND USING THEREOF | GENECOPOEIA, INC. (US) | 2011-07-14 | — | — | WO | claimed |
| US-10174077-B2 | Method of inhibiting activity of cell surface fibroblast activation protein alpha | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2019-01-08 | — | — | US | disclosed |
| US-10155789-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2018-12-18 | — | — | US | disclosed |
| US-20170260231-A1 | Substrates and Inhibitors of Prolyl Oligopeptidase and Methods of Use Thereof | UNIV OKLAHOMA (US) | 2017-09-14 | — | — | US | disclosed |
| US-9688722-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170066800-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | UNIV OKLAHOMA (US) | 2017-03-09 | — | — | US | disclosed |
| US-9527884-B2 | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150141660-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | disclosed |
| US-20150119330-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2015-04-30 | — | — | US | disclosed |
| EP-2844246-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | The Board of Regents of the University of Oklahoma (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8933201-B2 | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140024582-A1 | STABLE INSULIN FORMULATIONS AND METHODS OF MAKING AND USING THEREOF | GENECOPOEIA, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2013166438-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2013-11-07 | — | — | WO | disclosed |
| WO-2011085393-A1 | STABLE INSULIN FORMULATIONS AND METHODS OF MAKING AND USING THEREOF | GENECOPOEIA, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110144037-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2011-06-16 | — | — | US | disclosed |
| CN-101512338-A | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use thereof | MCKEE PATRICK A (US) | 2009-08-19 | — | — | CN | disclosed |
| US-20080057491-A1 | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-06 | — | — | US | disclosed |
| US-7144899-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20040073025-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
| WO-2002064559-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073025-A1 | Thrombin inhibitors | F2, F11, F10 | SLC1A2 4848/4885ARG1 167/4885ARG2 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.